| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that its Board of Directors and executive team have formally initiated a strategic review to explore the potential formation of a dedicated digital asset investment vehicle.
This initiative marks a bold step toward positioning the Company at the forefront of capital innovation, as it evaluates options to diversify its long-term treasury strategy. The prospective subsidiary—which has not yet been formed and remains under active consideration—would operate independently of Liminatus's core clinical pipeline and focus on digital asset allocation and blockchain-integrated financial structures.
If approved and executed, the Company anticipates targeting up to $500 million in potential capital formation through a combination of private placements, convertible instruments, equity line and other structured financing tools. All fundraising activities, if undertaken, would be conducted in full alignment with applicable SEC regulations and exemptions.
At this stage, no capital has been raised or committed, no agreements have been executed, and no third-party partnerships have been established. The internal review remains subject to final Board approval, regulatory compliance, and prevailing market conditions.
Liminatus is working in close coordination with experienced legal, financial, and regulatory advisors to determine the optimal structure, governance, and compliance framework for the proposed initiative. The Company will provide further disclosures as appropriate, in accordance with SEC and Nasdaq reporting requirements.
Posted In: LIMN
